I applaud the study by Schober et al1 in this issue of AJKD, which focuses on patients treated with dialysis to assess their attitudes and overall potential to engage in advocacy related to chronic kidney disease (CKD). As the study states, even though more than 25 million Americans live with CKD and more than 400,000 require maintenance dialysis therapy for kidney failure, funding for CKD research is relatively low and public awareness of the impact of the disease is limited. Although the Renal Support Network (RSN)—a national, patient-led, nonmedical support and advocacy group for individuals with CKD—was not mentioned by Schober et al, its members have first-hand knowledge of the advocacy limitations voiced by participants in this study.